- ￥1190 - 3190
- Solarbio
- 北京
- IA4450
- 2025年07月23日
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 保存条件：
Powder:2-8℃，2 years;Insolvent(母液):-20℃，6 months;-80℃，1 year
- 保质期：
Powder:2-8℃，2 years;Insolvent(母液):-20℃，6 months;-80℃，1 year
- 英文名：
AZ-304
- 库存：
现询
- 供应商：
北京索莱宝科技有限公司
- CAS号：
942507-42-8
- 规格：
100mg/50mg/25mg
| 规格： | 100mg | 产品价格： | ￥3190.0 |
|---|---|---|---|
| 规格： | 50mg | 产品价格： | ￥1990.0 |
| 规格： | 25mg | 产品价格： | ￥1190.0 |
| 基本信息 | |
| CAS | No.942507-42-8 |
| 英文名称 | AZ-304 |
| 别名 | 3-(2-氰基丙烷-2-基)-N-(3-((7-甲氧基-4-基)氨基)-4-甲基苯基)苯甲酰胺 |
| 分子式 | C27H25N5O2 |
| 分子量 | 451.52 |
| 溶解性 | Soluble in DMSO ≥10mg/mL;Soluble in Water ＜ 1mg/mL |
| 纯度 | ≥98% |
| 外观(性状) | White to off-white Solid |
| 储存条件 | Powder:2-8℃，2 years;Insolvent(母液):-20℃，6 months;-80℃，1 year |
| MDL | MFCD31812677 |
| SMILES | O=C(NC1=CC=C(C)C(NC2=C3C=CC(OC)=CC3=NC=N2)=C1)C4=CC=CC(C(C)(C#N)C)=C4 |
| 靶点 | Raf;c-FMS/CSF-1R;p38 |
| 通路 | MAPK;Angiogenesis; Protein Tyrosine Kinase/RTK |
| 背景说明 | AZ-304是新型,有效且具有ATP竞争性的野生型BRAF和V600E突变型BRAF以及野生型CRAF双重抑制剂,还能抑制CRAF, p38 和 CSF1R。 |
| 生物活性 | AZ304 is an ATP-competitive dual BRAF kinase inhibitor, potently inhibits wild type BRAF, V600E mutant BRAF and wild type CRAF, with IC50s of 79 nM, 38 nM and 68 nM, respectively. AZ304 also has significant effect on other kinases, such as p38 (IC50, 6 nM), CSF1R (IC50, 35 nM). Anti-tumor activity[1]. |
| In Vitro | AZ304(1 nM-100 μM)potently reduces ERK phosphorylation(p-ERK)，with a mean EC50 of 65 nM in the V600E mutant BRAF containing melanoma cell line A375，and EC50s of 52 nM，60 nM in the wild type BRAF melanoma cell line SK-MEL-31 with and without EGF[1]. AZ304 also potently inhibits p-p38 in both BRAF genetic statuses cell lines[1].AZ304(2 μM，36 and 48 hours)decreases BRAF，p-ERK，p-AKT and p-mTOR levels，increases p-EGFR in both BRAF V600E mutant and BRAF wild type cells. AZ304 down-regulates p-EGFR，inhibits p-ERK，more potently suppresses BRAF，ERK，AKT and mTOR signalling pathways in combination with C225[1]. |
| 细胞实验 | Compared with vehicle-treated controls，treatment with AZ304 or Cetuximab alone resulted in reduced tumor growth in both xenograft models. Furthermore，the AZ304 and Cetuximab combination caused dramatic tumour growth inhibition and even shrinking in the Caco-2 xenograft model.[1] |
| 细胞实验 | Female 4–6 weeks old athymic BALB/c nude mice were purchased from Shanghai SLAC Laboratory Animal Centre. RKO/Caco-2 cells(1 × 10^7)in 200 μl PBS were injected subcutaneously into the right scapular region of mice. After the average tumour size reached 150 – 200 mm^3，animals were randomly divided into 4 groups，each containing three mice and were treated with vehicle only(CON)which orally received 0.5% HPMC and injected with 0.9% saline，AZ304 only(AZ304 dissolved in 0.5% HPMC，10 mg/kg by oral gavage twice daily)，Cetuximab only(40 mg/kg by intraperitoneal injection twice per week)，or their combination(A+C)for 10 days. Tumors were measured with a caliper every 2 days，so did body weights. Tumor volume was calculated using the formula V = 1/2(width^2 × length). Mice were terminated by CO2 inhalation when the tumor diameters reached 1.5 cm，according to the protocol filed with the Guidance of Institutional Animal Care and Use Committee of China Medical University.[1] |
| 动物实验 | AZ304(0，0.1，1，10，100 μM，48 and 72 hours)dose-dependently inhibits the growth of RKO，HT-29，DiFi，and Caco-2，with GI50s of 4.539 μM，3.896 μM，4.987 μM，1.763 μM(48 hours)and 0.5032 μM，0.3887 μM，0.6354 μM，0.3772 μM(72 hours)，respectively[1]. |
| 激酶实验 | Briefly，the kinase activity of BRAF WT，BRAF V600E，or CRAF was measured using an AlphaScreen assay monitoring MEK1/2 phosphorylation at Ser217/221. For CDK2 and CDK4 kinases，activity was also measured by AlphaScreen，monitoring phosphorylation of biotin Rb peptide at Ser780. Similarly，MAP3K7，CSF1R，and JAK2 kinase activity were measured by phosphorylation of their biotinylated substrates MKK6 kinase-dead protein at Ser271/Thr275，or tyrosine phosphorylation of pEY or Tyk2 Tyr1054/1055 peptides，respectively. CSK，IGF1R，EGFR，FGFR1 and SRC kinase activity was measured using a sandwich ELISA detecting phosphorylated poly EAY peptide with a HRP conjugated phosphotyrosine antibody and TMB substrate，while p38 kinase activity was measured by monitoring phosphorylation of MBP protein with radiolabeled 33P-ATP in a filter binding format. All assays were screened under respective ATP Km conditions and inhibitor IC50s were derived from either 5(RAF kinases，CDK2，CDK4，MAP3K7，JAK2)，10(CSK，IGF1R，EGFR，FGFR1，SRC)or 11(p38，CSF1R)point compound dose response.[1] |
| 数据来源文献 | [1]. Ma R， et al. AZ304， a novel dual BRAF inhibitor， exerts anti-tumour effects in colorectal cancer independently of BRAF genetic status. Br J Cancer. 2018 May;118(11):1453-1463. |
| 单位 | 瓶 |
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验相关实验
你是否命里缺觉？午休是否有害健康？Nature 子刊给出答案
HCRTR1 和 HCRTR2 基因相关性预测促食素拮抗剂的心血管安全性 目前，促食素受体拮抗剂提供了一种新的治疗失眠的方法，而促食素受体激动剂目前正在开发用于治疗嗜睡症。鉴于上述 GWAS 中观察到食欲素通路变异 (HCRTR1 和 HCRTR2 变种) 与白天午睡行为相关联，同时，最近的研究表明哺乳动物促食素信号通路具有心脏保护功能，因此，研究人员探索了这些变异是否可以作为工具来预测食欲素受体作为药物靶点的心血管安全性。 为了测试这种潜在靶点的心血管副作用，他们使用了 HCRTR1 (rs
5+YiLLj4HREBXstjztk7uH3PDncf2sPhxRlMq6wGF+vZ2OlE8VGoBH85gWn/XYBn2ck48eAqDu+xwjbrU7h2Zz2aZ3fD6YWWeBFuzJv2yfAMMyYBFj4y5r7yqpgAE0jPBFRyolzbpihAeo1X9z5K2o2YlqOUxRTN25rQLQ+8+x4oVfFzvgFHklZM2raEadaIsxjVfI0wedUizB5fB7r8yR8TTr6mQAL8FlQgbB6KCTABJiAfgWD8ev0cIrh
2F+DwTquooTcizAj6Sh40arj1e+iWJ2ispgsbT801bWi9OaaVDQ0u7N9Rf22Q7je3ypEkT/aXtAx/4gHh20RbetchuWXizve3YY/3L0LGHHqt8Cva+97zf/vEfvyYb4imWXpTxLz8m4rvgjodswc3X26Xnn2o3LbjZPv/Fv5GGuGa33/ZzO2n2HD17NAEWeUXwmQh44uy32U+uutL+69e+6jjedfsddvSxx3m8xNNFQ67wipqQKHyESZ35
技术资料暂无技术资料 索取技术资料
IA4450 AZ-304 抑制剂/拮抗剂/激动剂 索莱宝
￥1190 - 3190
